EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach

Autumn M McKnite iD, Abdullah Hamadeh iD, J Porter Hunt, Danielle J Green iD, Carina Imburgia, Aviva Whelan iD, Rachel Hudson, Andrew Chevalier, Cheryl L Mathis, Michelle J Yang, Jamie P Dwyer, Andrea Edginton iD und 1 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2026-05 · 15 (5)

DOI: 10.1002/psp4.70240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 25.04.2026. Verfasst von Autumn M McKnite und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Midazolam, Models, Biological, Continuous Renal Replacement Therapy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center, NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Obstetrics and Pediatric Pharmacology and Therapeutics Branch (OPPTB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Children supported with continuous renal replacement therapy have high mortality rates ranging from 30% to 70%. The cause of this high mortality is multifactorial and includes ineffective drug dosing and altered drug pharmacokinetics. Changes in drug exposure can result from (1) underlying disease; and (2) direct drug interaction and/or clearance by the circuit. The extent to which these effects interact and modify drug pharmacokinetics is currently unknown for most drugs. As a result, there is little guidance on drug dosing in this population. We have developed a combined ex vivo and physiologically‐based pharmacokinetic modeling approach to mechanistically model midazolam concentrations in pediatric patients on continuous renal replacement therapy. Published models were scaled to children and modified to incorporate patient‐specific physiological changes due to critical illness including residual renal function, hematocrit, albumin levels, and inflammation‐induced downregulation of drug metabolizing enzymes. A compartment representing the dialysis circuit was created, parameterized using ex vivo data, and added to the full child physiological based pharmacokinetic model. The child model was then used to predict drug exposure in children undergoing continuous renal replacement therapy. Observed data from an ongoing opportunistic pharmacokinetic study were used to validate the models. The midazolam continuous renal replacement therapy models accurately represented drug concentrations and were used to predict optimal drug dosing. Model informed dosing for all age groups fell within the standard dosing range suggesting no changes are needed during continuous renal replacement therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MidazolamModels, BiologicalContinuous Renal Replacement TherapyHumansChildChild, PreschoolMaleFemaleInfantAdolescentDose-Response Relationship, Drug

Stichwörter der Autor:innen

continuous renal replacement therapyex vivomidazolampediatricsphysiologically‐based pharmacokinetic modeling

Substanzen

Midazolam

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
  • Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • University of Waterloo, School of Pharmacy, Waterloo, Ontario, Canada.
  • Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • Division of Neonatology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Autumn M McKnite, Abdullah Hamadeh, Danielle J Green, Aviva Whelan, Andrea Edginton

Förderung

  • Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Obstetrics and Pediatric Pharmacology and Therapeutics Branch (OPPTB)
  • National Institute of Child Health and Human Development
  • NHLBI NIH HHS
  • American Foundation for Pharmaceutical Education Pre-Doctoral Research Fellowship in Pharmaceutical Sciences
  • Thrasher Research Fund
  • NIDDK NIH HHS

Zitieren

APA

McKnite, A. M., Hamadeh, A., Hunt, J. P., Green, D. J., Imburgia, C., Whelan, A., Hudson, R., Chevalier, A., Mathis, C. L., Yang, M. J., Dwyer, J. P., Edginton, A., & Watt, K. M. (2026). Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach. CPT: Pharmacometrics & Systems Pharmacology, 15(5). https://doi.org/10.1002/psp4.70240

Vancouver

McKnite AM, Hamadeh A, Hunt JP, Green DJ, Imburgia C, Whelan A, et al. Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(5). doi:10.1002/psp4.70240

BibTeX
@article{McKnite2026,
  author = {McKnite, Autumn M and Hamadeh, Abdullah and Hunt, J Porter and Green, Danielle J and Imburgia, Carina and Whelan, Aviva and Hudson, Rachel and Chevalier, Andrew and Mathis, Cheryl L and Yang, Michelle J and Dwyer, Jamie P and Edginton, Andrea and Watt, Kevin M},
  title = {Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/psp4.70240}
}
Kostenlos starten →